ReviewCancers2022
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- KRASScience advances · 2026Article
- Machine learning enables efficient and effective affinity maturation of nanobodies.bioRxiv : the preprint server for biology · 2026Article
- Microsystem technologies for accelerating the discovery and translation of immunotherapies.Nature reviews. Drug discovery · 2026Review
- Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges.Veterinary research communications · 2025Review
- Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy.Frontiers in immunology · 2025Article
- Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus.Cancer gene therapy · 2024Article
- AttABseq: an attention-based deep learning prediction method for antigen-antibody binding affinity changes based on protein sequences.Briefings in bioinformatics · 2024Article
- Production of a Ribosome-Displayed Mouse scFv Antibody Against CD133, Analysis of Its Molecular Docking, and Molecular Dynamic Simulations of Their Interactions.Applied biochemistry and biotechnology · 2024Article
- Revolutionizing antiviral therapy with nanobodies: Generation and prospects.Biotechnology reports (Amsterdam, Netherlands) · 2023Review
- A Novel Strategy for Screening Tumor-Specific Variable Domain of Heavy-Chain Antibodies.International journal of molecular sciences · 2023Article
- Phage Display-Derived Peptides and Antibodies for Bacterial Infectious Diseases Therapy and Diagnosis.Molecules (Basel, Switzerland) · 2023Review
- Selection of Affibody Affinity Proteins from Phagemid Libraries.Methods in molecular biology (Clifton, N.J.) · 2023Article
- New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC.Cancers · 2022Article
- A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.International journal of molecular sciences · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies are among the most powerful therapeutics in modern medicine. Since the approval of the first therapeutic antibody in 1986, monoclonal antibodies keep holding great expectations for application in a range of clinical indications, highlighting the need to provide timely and sustainable access to powerful screening options. However, their application in the past has been limited by time-consuming and expensive steps of discovery and production. The screening of antibody repertoires is a laborious step; however, the implementation of next-generation sequencing-guided screening of single-chain antibody fragments has now largely overcome this issue. This review provides a detailed overview of the current strategies for the identification of monoclonal antibodies from phage display-based libraries. We also discuss the challenges and the possible solutions to improve the limiting selection and screening steps, in order to keep pace with the increasing demand for monoclonal antibodies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.